Guardant Health's Guardant360 is a 'liquid biopsy' that analyzes tumor DNA from a blood sample, offering a less invasive, cheaper, and safer alternative to traditional tissue biopsies for late-stage cancer patients.
The company's proprietary technology improves DNA sequencing accuracy by 1,000-10,000x, enabling high sensitivity and 99.3% concordance with tissue biopsies for the mutations it detects.
Guardant Health is experiencing rapid adoption, processing over 20,000 samples annually, with a multi-faceted business model that includes payers, hospitals, and a fast-growing segment partnering with pharmaceutical companies for clinical trial screening.
The long-term vision is to expand from managing late-stage cancer to monitoring for recurrence in survivors and ultimately creating an early-detection cancer screening test for the general population as part of a routine physical.
12 quotes
Concerns Raised
The test has lower sensitivity (approx. 40%) for brain cancers due to the blood-brain barrier.
Broad physician adoption is a slow process, as it can take years for medical professionals to change established clinical behaviors.
Opportunities Identified
Expanding into the market for cancer recurrence monitoring for 15 million cancer survivors.
The long-term, multi-billion dollar market for an early-stage cancer screening test suitable for the general population.
The fastest-growing business segment is partnering with pharmaceutical companies to screen patients for clinical trials.